Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation
- Conditions
- Evidence of Liver Transplantation
- Registration Number
- NCT02695979
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.
- Detailed Description
Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- End stage liver disease, chronic liver failure, orthotopic liver transplantation
Read More
Exclusion Criteria
- Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Macrophage Migration Inhibitory Factor in human serum, liver graft effluent and urine 24 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Medical University Vienna
🇦🇹Vienna, Austria